Dr. Emmanuel Antonarakis, MB CHB

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of New South Wales / Faculty Of Medicine

  Medical School

• Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects, 2018-10-04

• Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide, 2018-02-10

• T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer, 2020-03-15

• Analytic Validation of RNAIn SituHybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer, 2016-05-10

• PARP inhibition - not all gene mutations are created equal, 2021-02-26

• Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion, 2017-01-03

• Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer, 2017-10-30

• Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival, 2018-06-01

• Germline Genetic Testing in Advanced Prostate Cancer - Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium, 2019-04-18

• The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited, 2021-01-06

• Multiparametric Whole-Body MRI with Diffusion-Weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases from Solid Tumors, 2018-04-04

• Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond, 2023-04-19

• Homologous recombination deficiency (HRD) score in germlineBRCA2- versusATM-altered prostate cancer, 2021-01-18

• The STAMPEDE trial: paradigm-changing data through innovative trial design, 2016-10-03

• A non-comparative randomized phase II study of two doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive prostate cancer, 2011-08-04

• Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer, 2020-06-11

• A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent, 2022-07-01

• Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial, 2017-11-07

• Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer, 2019-06-05

• Genomic and Clinical-Pathologic Characterization ofATM-deficient Prostate Cancer, 2020-07-21

• Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022, 2022-12-06

• Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer, 2017-09-01

• Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium, 2018-08-16

• Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer, 2020-03-26

• Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies, 2014-02-19

• Expression of AR-V7 and ARv567esin circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY, 2018-10-09

• Prostate angiosarcoma: is there any association with previous radiation therapy?, 2012-05-15

• A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS), 2020-06-01

• High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer, 2013-11-14

• Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial, 2011-10-22

• Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2ndgeneration androgen receptor signaling inhibitors, 2020-09-28

• Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience, 2019-08-13

• Enzalutamide: The emperor of all anti-androgens, 2012-10-27

• Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy, 2021-08-16

• Growth factor and signaling pathways and their relevance to prostate cancer therapeutics, 2014-04-18

• Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations, 2019-04-18

• MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression, 2023-03-10

• Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide, 2016-07-12

• Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy-Focus on Prostate Cancer, 2013-07-16

• PARP inhibitors in prostate cancer: time to narrow patient selection?, 2020-07-07

• Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype, 2019-08-07

• Association between pathogenic germline mutations inBRCA2andATMand tumor-infiltrating lymphocytes in primary prostate cancer, 2021-09-17

• Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy, 2019-07-26

• Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort, 2016-05-06

• MSH2 Loss in Primary Prostate Cancer, 2017-08-08

• Abiraterone for the Treatment of Advanced Prostate Cancer, 2012-10-25

• Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone, 2014-07-22

• Management of metastatic castration-resistant prostate cancer, 2013-02-07

• The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer, 2020-06-01

• Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer, 2016-11-08

• A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance, 2020-10-19

• An Immunohistochemical Signature Comprising PTEN, MYC, and Ki67 Predicts Progression in Prostate Cancer Patients Receiving Adjuvant Docetaxel After Prostatectomy, 2012-06-06

• CDK12Deficiency and the Immune Microenvironment in Prostate Cancer, 2020-11-16

• Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?, 2008-10-28

• PD-1/PD-L1 Pathway Inhibitors in Advanced Prostate Cancer, 2018-04-24

• Microsatellite instability in prostate cancer by PCR or next-generation sequencing, 2018-04-17

• Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products, 2022-09-30

• Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with non-hormonal agents: Combined analysis of four phase-2 trials, 2014-11-11

• Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study, 2019-03-13

• Paraneoplastic Palmar Fasciitis and Polyarthritis Syndrome in a Patient With Advanced Prostate Cancer, 2013-06-29

• CDK12 inactivation across solid tumors: an actionable genetic subtype, 2019-05-10

• Neuroendocrine Differentiation in Usual-Type Prostatic Adenocarcinoma: Molecular Characterization and Clinical Significance, 2020-07-10

• The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer, 2014-01-24

• ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems, 2023-04-14

• Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer, 2021-04-07

• A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells, 2015-06-05

• Targeting the spectrum of immune checkpoints in prostate cancer, 2021-07-15

• Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel, 2014-02-14

• The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer, 2012-06-15

• Preclinical Study usingMalat1Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9®to Suppress Enzalutamide-resistant Prostate Cancer Progression, 2017-05-18

• A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study, 2015-11-18

• Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer, 2017-03-29

• Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer, 2018-06-19

• Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer Patients with and without Prior Abiraterone Acetate and Prednisone, 2017-02-17

• Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer, 2021-10-13

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer, 2023-05-15

• Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer, 2016-05-13

• Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer, 2018-01-25

• Association of B7-H3 Expression with Racial Ancestry, Immune Cell Density, and AR Activation in Prostate Cancer, 2022-03-25

• GermlineBLMmutations and metastatic prostate cancer, 2019-11-05

• Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer, 2013-07-10

• A Phase I Study of the Antibody Drug Conjugate ASG-5ME, an SLC44A4-targeting Antibody Carrying Auristatin E, in Metastatic Castration-Resistant Prostate Cancer, 2019-02-06

• Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors, 2019-05-10

• AR-V7 and treatment selection in advanced prostate cancer: are we there yet?, 2018-09-18

• Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer, 2020-08-14

• A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA, 2014-09-07

• Molecular heterogeneity of localized prostate cancer: more different than alike, 2017-03-24

• Lenalidomide Modulates IL-8 and Anti-Prostate Antibody Levels in Men with Biochemically Recurrent Prostate Cancer, 2011-07-11

• Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: Association of Gleason score and tumor stage, 2018-08-31

• Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases, 2012-04-17

• Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis, 2017-11-21

• Clinical and genomic features ofSPOP-mutant prostate cancer, 2021-11-15

• CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer, 2018-01-16

• Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer, 2022-11-02

• Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer, 2021-01-15

• Targeting ELK1: a wELKome addition to the prostate cancer armamentarium, 2018-10-31

• A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts, 2020-07-02

• Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies, 2018-07-09

• Very high risk localized prostate cancer: definition and outcomes, 2013-11-05

• AR Splicing Variants and Resistance to AR Targeting Agents, 2021-05-23

• Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics, 2022-01-11

• TMPRSS2and COVID-19: Serendipity or opportunity for intervention?, 2020-04-10

• Tumorigenic potential of circulating prostate tumor cells, 2013-03-05

• CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors, 2020-04-21

• Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide, 2021-04-05

• Stereotactic Ablative Radiation Therapy for Oligometastatic Prostate Cancer Delays Time to Next Systemic Treatment, 2018-09-06

• Surgical Resection of Malignant Melanoma Metastatic to the Pancreas: Case Series and Review of Literature, 2013-06-19

• A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA), 2019-06-13

• The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer, 2017-08-01

• Prostate angiosarcoma: a case report and literature review, 2012-02-17

• The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer, 2014-06-11

• A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer, 2019-07-30

• Nivolumab plus Ipilimumab, with or without Enzalutamide, in AR-V7-expressing Metastatic Castration-Resistant Prostate Cancer: A Phase-2 Nonrandomized Clinical Trial, 2021-02-26

• Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations, 2018-10-15

• Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?, 2014-12-30

• Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer, 2023-03-31

• Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naive prostate cancer cells, 2020-09-10

• Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database, 2010-11-23

• A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE), 2017-06-29

• A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer, 2013-01-13

• Androgen Receptor Variant-Driven Prostate Cancer II: Advances in Laboratory Investigations, 2020-03-05